New MS drug trial opens for kids, aims to reduce relapses
NCT ID NCT07220252
Summary
This study is testing a medication called ublituximab in children and teenagers aged 10 to 18 with relapsing multiple sclerosis (RMS). The main goals are to see how the drug works in the body, compare its effectiveness to another standard MS drug (fingolimod), and monitor its long-term safety. The study will involve about 240 participants and includes an extended follow-up period to track outcomes over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.